Document is current
Any future updates will be listed below
-
Authors
Apley, Kyle D.
Bass, Lindsay E.
King, Jaylyn
Downes, Grant
Wang, Kristen
Forchetti, Mason V.
Moore, Daniel J.
Kendall, Peggy
Bonami, Rachel H.
Berkland, Cory J. https://orcid.org/0000-0002-7164-7886
-
Funding
Funding for this research was provided by:
Leona M. and Harry B. Helmsley Charitable Trust (Leona M. and Harry B. Helmsley Charitable Trust)
National Science Foundation (1451158, 1540502, 1940699)
Foundation for the National Institutes of Health (R01 DK131070)
Foundation for the National Institutes of Health (K12 HD043483)
Foundation for the National Institutes of Health (T32 AR059039)
Foundation for the National Institutes of Health (F31 DK141224)
- License Information
-
More Information
Article History
Accepted: 18 April 2025
First Online: 22 May 2025
Declarations
:
: These studies were approved by the Vanderbilt Institutional Review Board, and Ancillary Study Approval was granted by Type 1 Diabetes TrialNet. Written informed consent was received for each participant prior to study enrollment.
: The authors declare the following competing financial interests: KDA and CJB are co-inventors on a patent application related to this work filed by the University of Kansas on conjugates with inhibitory receptor ligands to limit the activation of insulin-binding B cells (WO2022165016A1). Authors LEB, JK, GD, KW, MVF, DJM, PK, and RHB declare they have no conflict of interest.
